May 27, 2026

Women Overdue for Cancer Screenings

More than 80% of women who were partially up to date reported a wellness visit in the prior year, suggesting missed opportunities for screening engagement in primary care.

Conexiant

May 27, 2026

Postop Pain Differs by Vitamin D Status

Patients with preoperative vitamin D deficiency had higher postoperative pain scores and opioid use after mastectomy, including more than triple the odds of moderate to severe pain within 24 hours of surgery.

Conexiant

May 27, 2026

Top 10 Evidence-Based Essentials in Family Medicine

A structured framework of guidelines, trials, therapies, and tools used in clinical practice.

Conexiant

May 20, 2026

FDA Approves Expanded Liquid Biopsy Panel

Updated liquid biopsy combines genomic and epigenomic profiling for companion diagnostic use across multiple tumor types.

Conexiant

May 19, 2026

Top 10 High-Impact Clinical Guidance Updates for Board-Certified Physicians

A structured framework of guidelines, consensus statements, therapies, and clinical tools used across practice.

Conexiant

May 19, 2026

IPS Could Minimize GI Effects in Treating Iron Deficiency

Review summarizes pharmacokinetic and clinical data on iron protein succinylate across patients with iron deficiency and iron deficiency anemia.

Conexiant

May 19, 2026

CT Use May Add to Future Cancer Burden

Researchers projected approximately 103,000 future cancers associated with computed tomography examinations performed in the US in 2023.

Conexiant

May 18, 2026

Whole-Body MRI: Evidence Gap Widens

Two radiologists argue the for-profit scan industry has outrun the evidence — and the math warrants scrutiny.

Conexiant

May 18, 2026

Top 10 States with the Lowest Costs for Running a Medical Practice

These 10 states posted some of the lowest 2026 Medicare practice expense GPCI among states that CMS treats as a single statewide locality, with broader price levels and selected malpractice or tax indicators adding context.

Conexiant

May 15, 2026

Why FDA Said No to a Melanoma Drug

Questions over trial design and political pressure shadowed the rejection of Replimune’s RP1 treatment.

Kff Health News